Outlook Therapeutics Inc

For the period ended Sep 30, 2024. Filed Dec 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Dec 27, 2024

OTLK$0.46+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Consolidated Statements of Stockholders’ Equity (Deficit)

· · · · · · · · · · · · · ·
· · Stockholders’ Equity (Deficit)
· · Common Stock · · Additional · · Accumulated · · Total Stockholders’
· Shares · Amount · Paid-in Capital · Deficit · Equity (Deficit)
Balance at October 1, 2022	11,365,486	113,655	417,558,434	(408,935,518)	8,736,571
Issuance of common stock in connection with conversion of convertible promissory note	625	6	24,994	—	25,000
Sale of common stock, net of issuance costs (Note 9)	1,646,722	16,467	30,219,834	—	30,236,301
Stock-based compensation expense	—	—	5,547,019	—	5,547,019
Net loss	—	—	—	(58,982,668)	(58,982,668)
Balance at September 30, 2023	13,012,833	130,128	453,350,281	(467,918,186)	(14,437,777)
Issuance of common stock in connection with conversion of convertible promissory note	1,607,093	16,072	11,233,928	—	11,250,000
Sale of common stock, net of issuance costs (Note 9)	9,285,709	92,857	—	—	92,857
Stock-based compensation expense	—	—	5,385,124	—	5,385,124
Net loss	—	—	—	(75,366,714)	(75,366,714)
Balance at September 30, 2024	23,905,635	$239,057	$469,969,333	$(543,284,900)	$(73,076,510)

See accompanying notes to consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.